17.5C
Delhi
Friday, January 22, 2021

Animal study proved Covid vaccine’s efficacy: Bharat Biotech

- Advertisement -

covaxin biotechHyderabad, Sep 11 (IANS) Vaccine maker Bharat Biotech on Friday announced that the animal trials of its Covid-19 vaccine candidate Covaxin were successful.

It said the results demonstrated the protective efficacy of the vaccine in a live viral challenge model.

“Bharat Biotech proudly announces the animal study results of COVAXIN – These results demonstrate the protective efficacy in a live viral challenge model,” tweeted the Hyderabad-based firm.

It said the data from the study on primates substantiate the immunogenicity of the vaccine candidate.

According to a detailed statement attached to the tweet, Bharat Biotech developed and assessed the protective efficacy and immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) or Covaxin in rhesus macaques (Macaca mulata). Twenty macaques were divided into four groups of five animals each.

READ ALSO:  YouTube brings back 1080p streaming option in India

“One group was administered a placebo while three groups were immunised with three different vaccine candidates at 0 and 14 days. All the macaques were challenged with SARS-CoV-2 14 days after the second dose. The protective response was observed with increasing SARS-CoV-2 specific IgG and neutralising antibody titres from third week post-immunisation,” it said.

“Viral clearance was observed from bronchoalveolar lavage fluid, nasal swab, throat swab, and lung tissues at 7 days post-infection in the vaccinated groups. No evidence of pneumonia was observed by histopathological examination in vaccinated groups, unlike the placebo group which showed features of interstitial pneumonia and localisation of viral antigen in the alveolar epithelium and macrophages by immunohistochemistry.”

“To summarize, the vaccine candidate was found to generate robust immune responses. Thus, preventing infection and disease in the primates upon high amounts of exposure to live SARS-CoV-2 virus,” it added.

READ ALSO:  Citizenship Bill 2019 clears Rajya Sabha with 125 Ayes and 105 Noes

The vaccine is being evaluated in Phase-I clinical trials in India.

The vaccine maker early this month received approval from the Central Drugs Standard Control Organisation to conduct the Phase-II trials.

READ ALSO:  Epidemic Diseases Bill passed in LS to protect frontline Covid workers

Bharat Biotech had announced on June 29 that it successfully developed Covaxin in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).

The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous, inactivated vaccine candidate has been developed and manufactured in Bharat Biotech’s high containment facility located in Genome Valley, Hyderabad.

Source: IANS

India Updates
India Updates is an independent news & Information website. Follow us for regular updates on News and Information.

Follow Us On

Related News

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Trending Topics In India

Covid 19 India Updates

Trending News In India

Trending Showbiz

Trending Sports

Latest Trending News In India

Data harvesting: CBI books Cambridge Analytica, another firm

New Delhi, Jan 22 (IANS): The CBI has registered a case against UK-based Cambridge Analytica and Global Science Research Limited in a case of alleged...

JLF’s 14th edition to return virtually from Feb 19-28

New Delhi, Jan 22 (IANS) Dubbed the “greatest literary show on Earth”, the Jaipur Literature Festival (JLF) returns in a virtual avatar from February 19-28...

Too early to say when curbs will be lifted: UK PM

London, Jan 22 (IANS) UK Prime Minister Boris Johnson said that it was "too early to say when restrictions will be lifted" as coronavirus...

Germany’s tough Covid-19 lockdown beginning to pay off: Merkel

Berlin, Jan 22 (IANS) The ongoing tough Covid-19 lockdown in Germany has begun to pay off as the country has witnessed a decline in...